Rexahn: BIO CEO & Investor Conference (Rexahn Pharmaceuticals, Inc) - Feb 13, 2016 - "Stage 1 completed; safe and well tolerated at the doses tested to date"; "MTD established (250 mg/m2/day)"; "3 patients experienced stable disease persisting up to 115, 170, 383 days (as of Jan 6, 2016)"; "Preliminary evidence of dose-dependent tumor reduction: 125 mg/m2/day Dose Group: 16% tumor reduction; 4 cycles of therapy, 200 mg/m2/day Dose Group: 36% tumor reduction; 2 cycles of therapy"
P2a data • Oncology • Renal Cell Carcinoma
|